HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

W Lloyd Clark Selected Research

aflibercept

3/2024Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
1/2023Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
9/2021Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
7/2017Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study.
1/2017Integrated results from the COPERNICUS and GALILEO studies.
1/2017Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
2/2016Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
3/2015Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
7/2014Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
3/2013Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


W Lloyd Clark Research Topics

Disease

13Macular Edema
01/2023 - 05/2012
8Macular Degeneration (Age-Related Maculopathy)
03/2024 - 07/2017
6Retinal Vein Occlusion
01/2017 - 05/2012
2Diabetic Retinopathy (Retinopathy, Diabetic)
09/2021 - 07/2017
2Inflammation (Inflammations)
10/2020 - 11/2016
2Uveitis
10/2020 - 11/2016
1Cataract (Cataracts)
07/2023
1Retinal Diseases
01/2023
1Epilepsy (Aura)
02/2018
1Microaneurysm
01/2017
1Panuveitis
11/2016
1Stroke (Strokes)
03/2015
1Pneumonia (Pneumonitis)
03/2015
1Retinopathy of Prematurity (Retrolental Fibroplasia)
11/2014
1Myopia
11/2014
1Vitreous Hemorrhage
07/2014
1Epiretinal Membrane (Epiretinal Membranes)
04/2004
1Breast Neoplasms (Breast Cancer)
04/2004

Drug/Important Bio-Agent (IBA)

11afliberceptIBA
03/2024 - 05/2012
6Ranibizumab (Lucentis)FDA Link
07/2023 - 01/2017
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
09/2021 - 05/2012
2Sirolimus (Rapamycin)FDA Link
10/2020 - 11/2016
2Bevacizumab (Avastin)FDA Link
01/2017 - 11/2014
2salicylhydroxamic acid (SHAM)IBA
07/2014 - 03/2013
1DEAE-Dextran (Pulsar)IBA
03/2024
1frovatriptan (Allegro)FDA Link
02/2018
1N-acetyltryptophanamide (NATA)IBA
01/2018
1Adrenal Cortex Hormones (Corticosteroids)IBA
11/2016

Therapy/Procedure

5Injections
07/2023 - 03/2013
5Lasers (Laser)
01/2019 - 11/2014
3Therapeutics
09/2021 - 07/2017
2Light Coagulation
01/2017 - 03/2015
1Retreatment
01/2018
1Intravitreal Injections
05/2012
1Vitrectomy
04/2004